Fausto J. Rodriguez, MD

Fausto Rodriguez, MD

Clinical Professor, Department of Pathology and Laboratory Medicine





Anatomic Pathology, Mayo Clinic College of Medicine, Rochester, MN, 2005
Neuropathology, Mayo Clinic College of Medicine, Rochester, MN, 2007
Neuro Oncology Res., Mayo Clinic College of Medicine, Rochester, MN, 2008


MS, Mayo Clinic College of Medicine, Rochester, MN, 2011
MD, University of Missouri-Columbia, 2002
BS, University of Missouri-Columbia, 1996
BA, University of Missouri-Columbia, 1996


Anatomic Pathology, Mayo Clinic College of Medicine and Science, 2005

Board Certifications

Molecular Genetic Pathology, American Board of Pathology
Neuropathology, American Board of Pathology, 2007

Contact Information

Scientific Interests

Dr. Rodriguez' research interests include brain tumor biology, genomics, and inherited syndromes associated with tumors of the central and peripheral nervous system

Highlighted Publications

Nix JS, Yuan M, Imada EL, Ames H, Marchionni L, Gutmann DH, Rodriguez FJ. Global microRNA Profiling Identified miR-10b-5p as a Regulator of Neurofibromatosis 1 (NF1)-glioma Migration. Neuropathol Appl Neurobiol 2021;47:96-107

Yuan M, White D, Resar L, Bar E, Groves M, Cohen A, Jackson E, Bynum J, Rubens J, Mumm J, Chen L, Jiang L, Raabe E, Rodriguez FJ*, Eberhart CG*. Conditional reprograming culture conditions facilitate growth of lower grade glioma models. Neuro-Oncol 2021;23(5):770-782

Imada EL, Strianese D, Edward DP, alThaqib R, Price A, Arnold A, Al-Hussain H, Marchionni L, Rodriguez FJ. RNA-sequencing highlights differential regulated pathways involved in cell cycle and inflammation in orbitofacial neurofibromas. Brain Pathol 2021 32(1):e13007

Pallavajjala A, Haley L, Stinnett V , Adams E , Pallavajjala R , Huang J , Morsberger L , Hardy M, Long P , Gocke CD , Eshleman JR ,Rodriguez F*, Zou YS *. Utility of Targeted Next-Generation Sequencing Assay to Detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. Hum Pathol (advanced online publication)

Yuan M, Eberhart CG, Pratilas CA, Blakeley JO, Davis C, Stojanova M, Reilly K, Meeker AK, Heaphy CM, Rodriguez FJ. Therapeutic vulnerability to ATR inhibition in concurrent NF1 and ATRX-deficient/ALT-positive high-grade solid tumors. Cancers 2022; 14(12), 3015